Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial

International Immunopharmacology（2021）

引用 33|浏览15

暂无评分

摘要

•Favipiravir can significantly shorten SARS-CoV-2 RNA positive duration.•Favipiravir can increase negative conversion rate of virus in 30 days.•Favipiravir can improve the clinical symptoms of SARS-CoV-2 RNA recurrent positive.

查看译文

关键词

Favipiravir,SARS-CoV-2,COVID-19,Recurrent positive

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要